PDF(Pubmed)
Abstract：
There is currently no consensus to determine which advanced melanoma patients will benefit from targeted therapy, immunotherapy, or a combination of both, highlighting the critical need to identify early-response biomarkers to advanced melanoma therapy. The goal of this review is to provide scientific rationale to highlight the potential role of metabolic imaging to assess response to targeted and/or immune therapy in melanoma cancer. For that purpose, a brief overview of current melanoma treatments is provided. Then, current knowledge with respect to melanoma metabolism is described with an emphasis on major crosstalks between melanoma cell metabolism and signaling pathways involved in BRAF-targeted therapy as well as in immune checkpoint inhibition therapies. Finally, preclinical and clinical studies using metabolic imaging and/or profiling to assess response to melanoma treatment are summarized with a particular focus on PET (Positron Emission Tomography) imaging and 13C-MRS (Magnetic Resonance Spectroscopy) methods.
摘要：
目前尚无共识来确定哪些晚期黑色素瘤患者将从靶向治疗中受益。免疫疗法，或者两者的结合，强调了确定晚期黑色素瘤治疗的早期反应生物标志物的关键需求。这篇综述的目的是提供科学依据，以强调代谢成像在评估黑色素瘤对靶向和/或免疫治疗的反应中的潜在作用。为此,提供了当前黑素瘤治疗的简要概述。然后，介绍了目前有关黑色素瘤代谢的知识,重点介绍了黑色素瘤细胞代谢与BRAF靶向治疗以及免疫检查点抑制治疗中涉及的信号通路之间的主要交叉.最后,总结了使用代谢成像和/或谱分析评估黑色素瘤治疗反应的临床前和临床研究，特别关注PET（正电子发射断层扫描）成像和13C-MRS（磁共振波谱）方法。
